Unibest

Pharmaceutical intermediates

Resmetirom Intermediates

7 pharmaceutical intermediates for Resmetirom. Indication: Non-Alcoholic Steatohepatitis (NASH); Liver Cirrhosis.

提交项目All intermediates

About Resmetirom

Originator
Roche
Indication
Non-Alcoholic Steatohepatitis (NASH); Liver Cirrhosis
Approved Date
03/14/2024
NCE Patent
03/14/2029
DS/DP
09/12/2026

Available intermediates

7 intermediates currently listed for Resmetirom. Request specifications, documentation or a quotation for any item below.

Resmetirom intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one920509-28-0//
3,6-dichloro-4-isopropylpyridazine107228-51-3//
4-(Propan-2-yl)pyridazine-3,6-diol1903632-97-2//
3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)aniline(WXG00196)920509-27-9//
3,6-Dichloropyridazine141-30-0//
4-Amino-2,6-dichlorophenol5930-28-9//
N-CYANOACETYLURETHANE6629-04-5//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibRevumenibRibociclib Succinate

Building toward Resmetirom?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →